Get the Stockscreener App
4.62
5.48%
0.24
Contineum Therapeutics Inc stock is traded at $4.62, with a volume of 139.45K.
It is up +5.48% in the last 24 hours and down -34.56% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$4.38
Open:
$4.37
24h Volume:
139.45K
Relative Volume:
2.27
Market Cap:
$103.23M
Revenue:
-
Net Income/Loss:
$-35.46M
P/E Ratio:
-10.95
EPS:
-0.4218
Net Cash Flow:
$-34.00M
1W Performance:
+11.86%
1M Performance:
-34.56%
6M Performance:
-71.97%
1Y Performance:
-69.98%
1-Day Range:
$4.30
$4.88
1-Week Range:
$3.85
$4.88
52-Week Range:
$3.85
$22.00
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
4.62 | 103.23M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
Contineum Therapeutics Inc Stock (CTNM) Latest News
Contineum Therapeutics (CTNM) vs. Its Competitors Head-To-Head Survey - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $24.80 Consensus PT from Analysts - Defense World
Contineum Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Contineum Therapeutics Rings the Closing Bell - Nasdaq
How the (CTNM) price action is used to our Advantage - news.stocktradersdaily.com
Charles Schwab Investment Management Inc. Has $811,000 Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Charles Schwab Investment Management Inc. Buys 12,035 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - The AM Reporter
Bank of New York Mellon Corp Has $275,000 Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Long Term Trading Analysis for (CTNM) - news.stocktradersdaily.com
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - BioSpace
Analysts Set Contineum Therapeutics, Inc. (NASDAQ:CTNM) Target Price at $24.80 - Defense World
(CTNM) Investment Report - news.stocktradersdaily.com
Jones Trading Begins Coverage on Contineum Therapeutics (NASDAQ:CTNM) - Defense World
Jones Trading Initiates Coverage of Contineum Therapeutics (CTNM) with Buy Recommendation - Nasdaq
JonesTrading Initiates Contineum Therapeutics at Buy With $23 Price Target -March 13, 2025 at 08:48 am EDT - Marketscreener.com
Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24% - Yahoo Finance
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum - Eagle-Tribune
Rhumbline Advisers Acquires 2,191 Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics’ (CTNM) “Overweight” Rating Reiterated at Morgan Stanley - Defense World
Robert W. Baird Cuts Contineum Therapeutics (NASDAQ:CTNM) Price Target to $16.00 - Defense World
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones - Marketscreener.com
Contineum reports Q4 EPS (56c), consensus (44c) - TipRanks
Contineum Therapeutics, Inc. SEC 10-K Report - TradingView
Objective long/short (CTNM) Report - Stock Traders Daily
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 - Marketscreener.com
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference - Business Wire
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights - Quantisnow
Contineum Therapeutics (CTNM) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Can Contineum's Upcoming Catalysts Turn The Tide In The Coming Months? - RTTNews
How To Trade (CTNM) - Stock Traders Daily
Chief Executive Officer Monia Brett P sold $1,229,463 worth of shares (38,843 units at $31.65), decreasing direct ownership by 18% to 180,683 units (SEC Form 4) - Quantisnow
Multiple Sclerosis FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight - Barchart
Contineum Therapeutics (CTNM) Projected to Post Quarterly Earnings on Wednesday - Defense World
(CTNM) Investment Analysis and Advice - Stock Traders Daily
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Barclays PLC Increases Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) 12% loss last week hit both individual investors who own 37% as well as institutions - Simply Wall St
New Oriental Education, Walgreens And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Contineum concludes enrolment in Phase II multiple sclerosis therapy trial - MSN
Enrollment complete in Phase 2 trial of remyelination therapy for RRMS - Multiple Sclerosis News Today
Contineum Therapeutics (NASDAQ:CTNM) Earns “Outperform” Rating from Royal Bank of Canada - Defense World
Contineum Therapeutics' (CTNM) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):